Home › Companies › Oruka Therapeutics, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Oruka Therapeutics, Inc.’s Form 8-K, filed June 4, 2026 (Item 5.07 on EDGAR). Page generated November 1, 2026.
Meeting of June 2, 2026: 4 items on Oruka Therapeutics, Inc.’s Form 8-K, filed June 4, 2026: 2 elected · 2 approved.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2025-2026
Explore Oruka Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Oruka Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 4, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Lawrence Klein | 43,918,579 | -- | -- | 63,593 | 1,267,194 | 99.8% | Elected | — |
| Elect Director: Chris Martin | 43,936,173 | -- | -- | 45,999 | 1,267,194 | 99.8% | Elected | — |
| 2. Ratification of Independent Auditor Appointment | 45,206,297 | 39,637 | 3,432 | -- | -- | 99.9% | Approved | — |
| 3. Approval of the Compensation of our Named Executive Officers on a Non-Binding, Advisory Basis | 43,033,967 | 875,114 | 73,091 | -- | 1,267,194 | 98% | Approved | — |
Source: Oruka Therapeutics, Inc., Form 8-K, filed with the SEC on June 4, 2026 — read the filing on EDGAR.
Each item below shows how the 211 asset managers that disclosed a Oruka Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
99.8% Majority: yes · of votes cast
Description as filed by funds: Election of Class II Directors for terms expiring in 2029: Chris Martin
Oruka Therapeutics, Inc.’s own tally for this item (“Elect Director: Chris Martin”): 43,936,173 for, 45,999 withheld, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected each of the two Class II directors proposed by the Company for election, to serve until the 2029 annual meeting of stockholders, and until their successors are elected and have qualified.”
Support: 99.8% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 6,975,958 | 0 | 0 | 0 | For |
| Vanguard | 2,187,100 | 0 | 0 | 0 | For |
| BlackRock | 1,157,726 | 0 | 0 | 0 | For |
| State Street | 709,423 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 405,297 | 0 | 0 | 0 | For |
| Charles Schwab | 322,103 | 0 | 0 | 0 | For |
| T. Rowe Price | 308,828 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 140,840 | 0 | 0 | 0 | For |
| Equitable | 95,132 | 0 | 0 | 0 | For |
| TIAA | 82,962 | 0 | 0 | 0 | For |
| American Century | 74,067 | 0 | 0 | 0 | For |
| Lincoln Financial | 52,957 | 0 | 0 | 0 | For |
| JPMorgan | 52,598 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 33,055 | 0 | 0 | 0 | For |
| Russell Investments | 31,780 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 29,318 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 27,000 | 0 | 0 | 0 | For |
| Voya | 24,453 | 0 | 0 | 0 | For |
| Brighthouse | 23,691 | 0 | 0 | 0 | For |
| John Hancock | 19,620 | 0 | 0 | 0 | For |
| Global X | 18,017 | 0 | 0 | 0 | For |
| Northern Trust | 17,896 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 17,543 | 0 | 0 | 0 | For |
| Pacific Life | 15,026 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 13,442 | 0 | 0 | 0 | For |
Fund voting reports, all 54 managers: 12,956,798 for. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Remedium Capital Partners, LLC | 1,565,661 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 1,565,661 for.
Combines 5 wordings of this item as funds reported it.
99.8% Majority: yes · of votes cast
Description as filed by funds: Election of Class II Directors for terms expiring in 2029: Lawrence Klein
Oruka Therapeutics, Inc.’s own tally for this item (“Elect Director: Lawrence Klein”): 43,918,579 for, 63,593 withheld, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected each of the two Class II directors proposed by the Company for election, to serve until the 2029 annual meeting of stockholders, and until their successors are elected and have qualified.”
Support: 99.8% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 6,975,958 | 0 | 0 | 0 | For |
| Vanguard | 2,187,100 | 0 | 0 | 0 | For |
| BlackRock | 1,157,726 | 0 | 0 | 0 | For |
| State Street | 709,423 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 405,297 | 0 | 0 | 0 | For |
| Charles Schwab | 322,103 | 0 | 0 | 0 | For |
| T. Rowe Price | 308,828 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 140,840 | 0 | 0 | 0 | For |
| Equitable | 95,132 | 0 | 0 | 0 | For |
| TIAA | 82,962 | 0 | 0 | 0 | For |
| American Century | 74,067 | 0 | 0 | 0 | For |
| Lincoln Financial | 52,957 | 0 | 0 | 0 | For |
| JPMorgan | 52,598 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 33,055 | 0 | 0 | 0 | For |
| Russell Investments | 31,780 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 29,318 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 27,000 | 0 | 0 | 0 | For |
| Voya | 24,453 | 0 | 0 | 0 | For |
| Brighthouse | 23,691 | 0 | 0 | 0 | For |
| John Hancock | 19,620 | 0 | 0 | 0 | For |
| Global X | 18,017 | 0 | 0 | 0 | For |
| Northern Trust | 17,896 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 17,543 | 0 | 0 | 0 | For |
| Pacific Life | 15,026 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 13,442 | 0 | 0 | 0 | For |
Fund voting reports, all 54 managers: 12,953,666 for, 3,132 withheld. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Remedium Capital Partners, LLC | 1,565,661 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 1,565,661 for.
Combines 9 wordings of this item as funds reported it.
98% Approved · of votes cast
Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of our named executive officers.
Oruka Therapeutics, Inc.’s own tally for this item (“3. Approval of the Compensation of our Named Executive Officers on a Non-Binding, Advisory Basis”): 43,033,967 for, 875,114 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, by non-binding advisory vote, the compensation of our named executive officers as disclosed in the Proxy Statement.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of Oruka Therapeutics, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “SAY ON PAY” (2 managers, 437 for).
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 6,975,958 | 0 | 0 | 0 | For |
| Vanguard | 2,187,099 | 1 | 0 | 0 | For |
| BlackRock | 1,157,726 | 0 | 0 | 0 | For |
| State Street | 709,134 | 289 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 405,297 | 0 | 0 | 0 | For |
| Charles Schwab | 322,103 | 0 | 0 | 0 | For |
| T. Rowe Price | 308,828 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 140,840 | 0 | 0 | 0 | For |
| Equitable | 95,132 | 0 | 0 | 0 | For |
| TIAA | 82,962 | 0 | 0 | 0 | For |
| American Century | 0 | 74,067 | 0 | 0 | Against |
| Lincoln Financial | 52,957 | 0 | 0 | 0 | For |
| JPMorgan | 52,598 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 33,055 | 0 | 0 | 0 | For |
| Russell Investments | 31,780 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 29,318 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 27,000 | 0 | 0 | 0 | For |
| Voya | 24,453 | 0 | 0 | 0 | For |
| Brighthouse | 23,691 | 0 | 0 | 0 | For |
| John Hancock | 19,620 | 0 | 0 | 0 | For |
| Global X | 18,017 | 0 | 0 | 0 | For |
| Northern Trust | 17,896 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 17,543 | 0 | 0 | 0 | For |
| Pacific Life | 15,026 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 13,442 | 0 | 0 | 0 | For |
Fund voting reports, all 57 managers: 12,907,356 for, 77,241 against. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 7,367,713 | 0 | 0 | 0 | For |
| Venrock Adviser, LLC | 4,180,907 | 0 | 0 | 0 | For |
| Fairmount Funds Management LLC | 3,705,262 | 0 | 0 | 0 | For |
| VIKING GLOBAL INVESTORS LP | 2,666,690 | 0 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 2,052,606 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 2,019,203 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 1,981,696 | 0 | 0 | 0 | For |
| Remedium Capital Partners, LLC | 1,565,661 | 0 | 0 | 0 | For |
| State Street | 1,331,819 | 4,713 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 1,076,829 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 931,358 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 914,296 | 0 | 0 | 0 | For |
| BlackRock | 873,045 | 14,795 | 0 | 0 | For |
| Avidity Partners Management LP | 760,424 | 0 | 0 | 0 | For |
| T. Rowe Price | 482,288 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 479,028 | 0 | 0 | 0 | For |
| SR ONE CAPITAL MANAGEMENT, LP | 430,330 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 411,006 | 0 | 0 | Against |
| Holocene Advisors, LP | 376,154 | 0 | 0 | 0 | For |
| Paradigm Biocapital Advisors LP | 370,590 | 0 | 0 | 0 | For |
| GREAT POINT PARTNERS LLC | 366,660 | 0 | 0 | 0 | For |
| Charles Schwab | 322,106 | 0 | 0 | 0 | For |
| Vanguard | 299,727 | 0 | 0 | 0 | For |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 258,427 | 2,233 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 202,106 | 0 | 0 | 0 | For |
Institutional-manager reports, all 166 managers: 37,177,262 for, 752,125 against, 221 abstained, 92,796 not voted. Showing the 25 largest; see all in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of Oruka Therapeutics, Inc. for its fiscal year ending December 31, 2026.
Oruka Therapeutics, Inc.’s own tally for this item (“2. Ratification of Independent Auditor Appointment”): 45,206,297 for, 39,637 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 6,975,958 | 0 | 0 | 0 | For |
| Vanguard | 2,187,100 | 0 | 0 | 0 | For |
| BlackRock | 1,157,726 | 0 | 0 | 0 | For |
| State Street | 709,423 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 405,297 | 0 | 0 | 0 | For |
| Charles Schwab | 322,103 | 0 | 0 | 0 | For |
| T. Rowe Price | 308,828 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 140,840 | 0 | 0 | 0 | For |
| Equitable | 95,132 | 0 | 0 | 0 | For |
| TIAA | 82,962 | 0 | 0 | 0 | For |
| American Century | 74,067 | 0 | 0 | 0 | For |
| Lincoln Financial | 52,957 | 0 | 0 | 0 | For |
| JPMorgan | 52,598 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 33,055 | 0 | 0 | 0 | For |
| Russell Investments | 31,780 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 29,318 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 27,000 | 0 | 0 | 0 | For |
| Voya | 24,453 | 0 | 0 | 0 | For |
| Brighthouse | 23,691 | 0 | 0 | 0 | For |
| John Hancock | 19,620 | 0 | 0 | 0 | For |
| Global X | 18,017 | 0 | 0 | 0 | For |
| Northern Trust | 17,896 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 17,543 | 0 | 0 | 0 | For |
| Pacific Life | 15,026 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 13,442 | 0 | 0 | 0 | For |
Fund voting reports, all 57 managers: 12,984,597 for. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Remedium Capital Partners, LLC | 1,565,661 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 1,565,661 for.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 50,167,623 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 13.91% |
| 2 | Vanguard | 4.36% |
| 3 | BlackRock | 2.31% |
| 4 | State Street | 1.41% |
| 5 | FRANKLIN STRATEGIC SERIES | 0.81% |
| 6 | Charles Schwab | 0.64% |
| 7 | T. Rowe Price | 0.62% |
| 8 | HARBOR FUNDS | 0.28% |
| 9 | Equitable | 0.19% |
| 10 | TIAA | 0.17% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 14.69% |
| 2 | Venrock Adviser, LLC | 8.33% |
| 3 | Fairmount Funds Management LLC | 7.39% |
| 4 | VIKING GLOBAL INVESTORS LP | 5.32% |
| 5 | RTW INVESTMENTS, LP | 4.09% |
| 6 | Deep Track Capital, LP | 4.02% |
| 7 | Polar Capital Holdings Plc | 3.95% |
| 8 | Remedium Capital Partners, LLC | 3.12% |
| 9 | State Street | 2.66% |
| 10 | PERCEPTIVE ADVISORS LLC | 2.15% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Fairmount Funds Management LLC | 29.01% | 13D |
| Entities affiliated with Fairmount Funds Management LLC | 22.25% | DEF14A |
| Peter Harwin | 22.25% | DEF14A |
| FMR (Fidelity) | 14.81% | 13F |
| FMR LLC | 14.47% | DEF14A |
| Entities affiliated with Venrock Healthcare Capital Partners | 9.79% | DEF14A |
| Venrock Healthcare Capital Partners III, L.P. | 9.08% | 13G |
| BlackRock | 7.03% | 13F |
| Capital World Investors | 6.78% | 13G |
| Entities affiliated with BlackRock, Inc. | 6.33% | DEF14A |
Percentages above are of 50,167,623 shares outstanding, as reported by Oruka Therapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Oruka Therapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 1, 2026; a live search always shows the current data.
At Oruka Therapeutics, Inc.'s shareholder meeting held June 2, 2026, in the 2025-2026 proxy season, 211 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 910 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of our named executive officers. — Oruka Therapeutics, Inc.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Oruka Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 4, 2026.
Oruka Therapeutics, Inc. proxy season coverage: 2025-2026 (this page).
Download data (CSV): ballot items · votes by manager · column guide.